GlassScriptPhysician profile
Susan Beth Marshall
NPI 1073672515
$5,221.69
in general payments reported to CMS, 2019-2025
16 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $367 · 2021: $619 · 2022: $741 · 2023: $663 · 2024: $1,148 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.65 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,476.54 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,042.57 | 2019-2025 | Biktarvy |
| Janssen Products, LP | $562.96 | 2019-2022 | |
| Novo Nordisk INC | $253.96 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.63 | 2022-2023 | |
| Kyowa Kirin, INC. | $145.50 | 2025 | |
| Lilly USA, LLC | $78.63 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $74.19 | 2022-2024 | Austedo Xr |
| Vifor Pharma, INC. | $42.00 | 2021-2023 | Veltassa |
| Napo Pharmaceuticals INC | $38.28 | 2019 | |
| Janssen Biotech, INC. | $30.20 | 2025 | Erleada |
| Glaxosmithkline, LLC. | $29.24 | 2023 | Shingrix, Trelegy Ellipta |
| Laborie Medical Technologies Corp. | $21.91 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Theratechnologies INC. | $21.02 | 2023 | Trogarzo, Egrifta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $15.36 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.